U.S. BioDefense, Inc.

Stem cell technology company receives UCL BioMedica option termination notice

Published in Pharma Law Weekly, September 6th, 2005

U.S. BioDefense, Inc. (UBDE) announced that its Option Agreement to license European Patent Application No. 02743434.9, and U.S. patent application 10/483,190 entitled "Liver cell progenitor and use for the treatment of liver disease" and related foreign applications was terminated by UCL BioMedica allegedly due to partial nonpayment.

U.S. BioDefense disputes the allegation claiming any partial payment schedules had been agreed to by UCL since negotiations have been ongoing for a full license agreement for the past few months.

U.S. BioDefense filed a Notice of Exercise prior to expiration and received a full term sheet for the license from UCL prior...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Law Weekly

Source: Pharma Law Weekly (2005-09-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry